Nearly 200 companies and institutions with perfect attendance at all nine CIIE editions set to return

Deep News11-03

In less than a week, the ninth China International Import Expo will be held in Shanghai.

At this year's CIIE, nearly 200 companies and institutions that have attended all nine editions will appear once again.

Having been here before, they still want to come back — what is the magnetic appeal of the CIIE?

Every year they hold a debut, and every year it becomes a hit.

Each year, LEGO Group, a "perfect attendance" exhibitor, launches new products as "global premieres" at the CIIE, many of them product sets inspired by Chinese culture.

Visitors look at the LEGO booth in the consumer goods exhibition area at the eighth CIIE. Photo by Xinhua reporter Chen Haoming.

"For example, the Chinese New Year-themed series that had its global premiere at the CIIE in past years was developed specifically for China but sold globally. We believe this can both make a meaningful contribution to spreading Chinese culture to the world and help us develop our brand while connecting with local Chinese culture," said Ma Shiming, general manager of LEGO Group China.

"For us, China is not just a consumer market," Ma Shiming said. Through the window of the CIIE, the company has deeply felt that the Chinese market is becoming a "weather vane" for global consumption, and with high-quality intellectual property protection and an internationalized, law-based business environment, it is boosting multinational companies' confidence in investing in China.

"The CIIE platform drives the efficient transformation of 'exhibits into products and products into hit products,' and we feel this firsthand."

Xu Daren, China president of Amorepacific, another "perfect attendance" exhibitor, said that at this year's CIIE, Amorepacific will bring four globally debuted products, bringing many cutting-edge innovations to Chinese consumers first and further demonstrating the group's high regard for the CIIE as a global new product launch platform and for the Chinese market, with concrete actions showing its firm determination and confidence to grow together with the local market.

CIIE "perfect attendance" exhibitors come with Chinese innovation, and they also bring "new friends."

Sheng Wenhao, Asia-Pacific CEO of Theland, who has already secured continuous participation for ten years, said that since the sixth CIIE, Theland has brought more New Zealand companies to exhibit. Many companies such as GRIN and Pacific Alpacas have moved from initially "going overseas as a group" to gaining a firm foothold in the Chinese market, and now exhibit independently at the CIIE. "The CIIE's platform effect and spillover effect continue to show. This year we will also join forces with New Zealand Trade and Enterprise to bring 33 companies to exhibit at once."

At the eighth CIIE, an exhibitor (left) introduces New Zealand dairy products from Theland to visitors. Photo by Xinhua reporter Wang Xiang.

"As an important platform connecting China and the world, the CIIE has created broad opportunities for exchange and cooperation in global medical technology innovation," said Geoff Martha, chairman and CEO of Medtronic. The CIIE has witnessed Medtronic's continuous progression from a global innovation "introducer" to a "implementer," and then to a "co-builder" of the local innovation ecosystem.

At the eighth CIIE, visitors stop to look at a Medtronic booth showcasing an ultra-hard guidewire product. Photo by Xinhua reporter Fang Zhe.

At present, the third phase of the Medtronic China fund is actively preparing to launch. Previously, two phases of the fund successfully invested in more than 10 Chinese local medical technology innovation companies, covering fields such as surgical robots, neuromodulation, and otolaryngology.

"We hope to build a 'two-way bridge,' further continue laying out around high-end medical device innovation and key links in the industrial chain, strengthen two-way links with Medtronic's global business, and help Chinese innovation develop globally," Geoff Martha said.

Doug Langa, global president and CEO of Novo Nordisk, said that this year Novo Nordisk will hold the global debut at the CIIE of NovoJet for the treatment of type 2 diabetes. As the latest achievement of the "China Synergy" project, this drug has a Chinese expert serving as principal investigator of the global phase 3 clinical study.

"The CIIE has become an important platform for us to deepen our presence in China. This year is our ninth consecutive year of participation, and many drugs first showcased at the CIIE have subsequently been launched in China one after another," Doug Langa said. (Reporter Zhou Rui)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment